Main Content

Development of neutralizing antibodies against MVA-MERS-S

The aim of the project is to identify and characterise particularly potent recombinant human monoclonal antibodies with a neutralising effect against the MERS coronavirus. The B cells for the development of the recombinant antibodies originate from the blood of study participants who were immunised with the MVA-MERS-S vaccine as part of a clinical trial.
The Institute of Virology Marburg is responsible for the identification of neutralising antibodies using validated MERS-CoV-based neutralisation assays.

Project Lead:

Michael Klüver

Staff members:

Gesche Gerresheim, Pauline Neubecker, Cornelius Rohde

Project Partners:

• University of Cologne
• University Clinic Hamburg-Eppendorf

Funding: